首页 > 市场调查报告书 > 医疗设备

整形外科齿科设备植牙关节移植

市场调查报告书

商品编码

1471989

生物植入物市场规模和预测、全球和区域份额、趋势和成长机会分析报告范围：按类型、材料和最终用户

Bio-Implants Market Size and Forecast, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type, Material, and End User

出版日期: 2024年03月22日 | 出版商:

The Insight Partners | 英文 150 Pages | 商品交期: 1-5个工作天内

价格

简介目录

根据我们关于「2031 年生物植入物市场预测- COVID-19 影响和全球分析- 按类型、材料和最终用户划分」的新研究，预计该市场将从2023 年的1178.2 亿美元增长到2023 年的1178.2 亿美元。预计 2023 年至 2031 年复合年增长率为 8.3%。市场成长归因于生活方式障碍负担的增加以及对微创外科手术的需求不断增长。不断增长的技术发展和政府倡议可能为生物植入市场提供成长机会。然而，产品召回和与植入材料相关的复杂性阻碍了生物植入市场的成长。

生物植入物是一种替代、增强或支撑生物结构的假体装置。它们由多种生物合成成分组成，例如组织工程产品以及胶原蛋白，包括合成皮肤。医疗保健技术的发展促进了生物植入物市场的成长。儘管医疗保健行业多年来取得了显着的技术进步，但严重疾病发病率的上升给生物植入物市场的成长带来了各种挑战。

2023年，北美占据全球生物植入市场最大的市场份额。该地区生物植入物市场的成长得益于慢性病盛行率的不断上升和医疗基础设施的改善。 2022 年 7 月，美国疾病管制与预防中心 (CDC) 的最新资料显示，冠状动脉疾病是最常见的心臟病类型之一，在美国约有2010 万20 岁及以上的成年人患有这种疾病。另外，根据CDC资料，美国每40秒就有一个人心臟病发作，即近80.5万人。慢性病发病率的上升预计将增加对生物植入物的整体需求，从而推动预测期内的市场成长。预计 2023 年至 2031 年，亚太地区的生物植入市场复合年增长率最高。该地区的市场成长归因于老年人口的成长、可支配收入的增加、医疗保健投资的增加和市场参与者的扩张，以及由于交通事故数量的增加而导致的脊髓损伤病例的增加。

不断增加的技术发展和政府措施为未来提供市场机会

3D列印、雷射技术和奈米技术等技术发展显着提高了生物植入物的生产。 3D 列印改变了生物植入物的设计和製造方法。该技术能够创建具有复杂几何形状、精确尺寸和客製化功能的患者专用植入物，从而实现更好的贴合性和功能。此外，将感测器、微电子和无线通讯整合到植入物中有助于即时监测患者的状况和健康状况。智慧植入物可以将资料传输给医疗保健提供者，从而实现远端监控和及时干预。

许多政府组织与进行健康研究和生产医疗设备的公司合作，以行销新的、更有效的设备。例如，2023年12月，新加坡南洋理工大学与新加坡中央医院（SGH）合作投资3D列印。该合作伙伴关係利用南洋理工大学新加坡 3D 列印中心和新加坡中央医院 3D 列印中心的设施和综合专业知识，研究和开发床边临床应用的相关技术。 2024 年 2 月，匹兹堡的一名工程师从美国国立卫生研究院获得了 557,000 美元，用于开展世界上首次骨科超材料植入体内研究，以改善脊椎损伤的治疗、修復和恢復。超材料比传统元素、合金或其他材料更先进，因为它们可以设计成提供各种所需的机械性能，包括超轻、超硬、超高强度密度比、顺应性和高弹性。此外，超材料植入物提供了很大的设计空间，因为它们可以由各种生物相容性材料製成。因此，预计不断增长的技术发展和政府倡议将为预测期内的市场成长提供成长机会。

基于类型的见解

根据类型，生物植入物市场分为心血管植入物、骨科植入物、牙科植入物、眼科植入物等。心血管植入物细分市场在 2023 年占据更大的市场份额。例如，2022 年 2 月，医疗技术公司雅培 (Abbott) 宣布全球首例患者植入无引线双腔起搏器系统，作为其 AVEIR DR i2i 关键临床试验的一部分。雅培实验性双腔无引线心律调节器的植入代表了无引线心律调节器技术的一个重要技术里程碑；这是世界上第一个进行关键试验的项目。

基于材料的见解

生物植入物市场依材料分为金属、陶瓷和聚合物。金属细分市场将在2023 年占据最大的生物植入市场份额。大市场占有率。例如，2021年12月，两片式陶瓷植体先驱DentalPoint宣布其最新产品ZERAMEX XT已获得美国FDA批准。该产品是美容假牙钛植体的无金属替代品，特别是在美容领域。

基于最终用户的见解

根据最终用户，市场分为医院和诊所以及门诊手术中心。医院和诊所细分市场在 2023 年将占据更大的生物植入市场份额，预计 2023 年至 2031 年期间复合年增长率将更高。

领先企业正在实施扩张、合作、推出新产品和获取新客户群等策略，以挖掘现有的商机。

2022年4月，骨科植入公司获得食品药物管理局批准，发布高瓣膜背侧扫描板。该产品帮助扩大了该公司的骨科创伤产品组合，以实现 OIC 的 DRPx 手腕骨折电镀系统的潜在临床植入，从而巩固其作为任何其他高价电镀系统最全面和价值驱动的替代品之一的地位。

2022 年 1 月，强生医疗器材公司 (JJMDC) 与 Microsoft 合作，增强并进一步开发 JJMDC 安全、合规的数位手术生态系统。

2021 年10 月，ScottCare Cardioangio Solutions 与Ninety One Holding, Inc. 签署协议，成为Ninety One 用于监测心臟植入设备的云端软体平台的主要分销商，为两家公司之间提供了有效的扩展合作伙伴关係。这使得 ScottCare Cardiological Solutions 能够直接向诊所提供 Ninety One 的云端平台，让诊所与其员工一起监控和管理病患资料。 Ninety One 的软体平台有助于将先进的资料科学与最新技术相结合，帮助分析和管理植入心臟设备的患者的复杂医疗资料。

美国食品药物管理局、疾病管制与预防中心 (CDC) 以及全球疾病负担研究是准备生物植入物市场报告时参考的主要和次要来源。

欧洲
- 德国
- 法国
- 义大利
- 西班牙
- 英国
- 欧洲其他地区
亚太
- 澳洲
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
中东和非洲
- 南非
- 沙乌地阿拉伯
- 阿联酋
- 中东和非洲其他地区
南美洲和中美洲
- 巴西
- 阿根廷
- 南美洲和中美洲其他地区

第 11 章：产业格局

併购
协议、合作、合资企业
新产品发布
扩张和其他策略发展

第 12 章：竞争格局

关键参与者的热图分析
公司定位与专注

第 13 章：生物植入物市场 - 主要公司概况

LifeNet Health
Smith & Nephew
Arthrex, Inc.
Clinic Lemanic
Alpha Bio Tec
MiMedx Group
Medtronic
St Jude Medical (Abbott)
Stryker Cooperation
DePuy Synthes
Biomet (Zimmer)
Exactech, Inc.
Cochlear Ltd
Straumann AG

第 14 章：附录

简介目录

Product Code: TIPHE100001101

According to our new research study on "Bio-implants Market Forecast to 2031 - COVID-19 Impact and Global Analysis - by Type, Material, and End User," the market is anticipated to grow from US$ 117.82 billion in 2023 to US$ 223.06 billion by 2031; it is estimated to register a CAGR of 8.3% during 2023-2031. Market growth is attributed to the increasing burden of lifestyle disorders and the growing demand for minimally invasive surgical procedures. Increasing technological developments and government initiatives will likely provide growth opportunities for the bio-implants market. However, product recalls and complexities associated with implant materials hinder the growth of the bio-implants market.

Bio-implants are prosthetic devices that replace, enhance, or support a biological structure. They consist of several biosynthetic components, such as tissue engineering products, along with collagen, including synthetic skin. Technological development in healthcare has contributed to the growth of the bio-implants market. Although the healthcare sector has made significant technological advancements over the years, the rising incidence of serious medical diseases has led to various challenges to the growth of the market for bio-implants.

North America accounted for the largest market share of the global bio-implants market in 2023. The market in this region is segmented into the US, Canada, and Mexico. The growth of the bio-implants market in the region is due to the growing prevalence of chronic diseases and better healthcare infrastructure. In July 2022, updated Centers for Disease Control and Prevention (CDC) data shows that coronary artery disease is one of the most common types of heart diseases, with approximately 20.1 million adults aged 20 and older living with the disease in the US. Additionally, according to CDC data, every 40 seconds, an individual suffers from a heart attack in the US, i.e., nearly 805,000 people. The rising incidence of chronic diseases is expected to increase the overall demand for bio-implants, which is expected to boost the market growth during the forecast period. Asia Pacific is expected to register the highest CAGR in the bio-implants market during 2023-2031. The market growth in the region is ascribed to the growing geriatric population, increasing disposable income, rising healthcare investments and expansion by market players, and increasing cases of spinal cord injuries due to the rising number of traffic accidents.

Increasing Technological Developments and Government Initiatives to Provide Market Opportunities in the Future

Technological developments such as 3D printing, laser technology, and nanotechnology have significantly improved the production of bio-implants. 3D printing has transformed the designing and manufacturing methodologies of bio-implants. This technology enables the creation of patient-specific implants with intricate geometries, precise dimensions, and tailored features, resulting in better fit and functionality. Further, integrating sensors, microelectronics, and wireless communication into implants helps in the real-time monitoring of the patient's condition and health. Smart implants can transmit data to healthcare providers, enabling remote monitoring and timely interventions.

Many government organizations work with companies conducting health studies and producing medical devices to market new and more effective devices. For example, in December 2023, Nanyang Technological University Singapore and Singapore General Hospital (SGH) collaborated to invest in the advancement of 3D printing. The partnership leverages the facilities and combined expertise of the Singapore Center for 3D Printing at NTU and the 3D Printing Center at SGH to research and develop relevant technologies for clinical applications in point-of-care settings. In February 2024, a Pittsburgh engineer received US$ 557,000 from the National Institutes of Health to conduct the world's first in vivo studies of orthopedic metamaterial implants to improve spinal injuries' treatment, repair, and recovery. Metamaterials are more advanced than traditional elements, alloys, or other materials because they can be designed to provide a wide range of desired mechanical properties, including ultralight, ultra-stiff, ultrahigh strength-to-density ratios, compliance, and high resilience. In addition, metamaterial implants offer great scope for design as they can be made from various biocompatible materials. Thus, increasing technological developments and government initiatives are anticipated to provide growth opportunities for the market growth during the forecast period.

Type -Based Insights

Based on type, the bio-implants market is segmented into cardiovascular implants, orthopedic implants, dental implants, ophthalmic implants, and others. The cardiovascular implants segment held a larger market share in 2023. The growth of the segment is due to rapid rise in research and development activities to develop novel cardiac implant products. For example, in February 2022, Abbott, a medical technology company, announced the world's first patient implantation of a leadless dual-chamber pacemaker system as part of its AVEIR DR i2i pivotal clinical trial. The implantation of Abbott's experimental dual-chamber leadless pacemaker represents a significant technological milestone for leadless pacemaker technology; it is the first in the world to be in a pivotal trial.

Material-Based Insights

The bio-implants market, based on material, is segmented into metals, ceramics, and polymers. The metals segment held the largest bio-implants market share in 2023. It is further expected to register the highest CAGR from 2023 to 2031. The ceramics segment is expected to hold the second-largest market share during the forecast period due to increasing approvals of ceramic products by regulatory authorities. For example, in December 2021, DentalPoint, the pioneer of two-piece ceramic implants, announced that it had received US FDA approval for its newest product, ZERAMEX XT. The product is a metal-free alternative to titanium implants for cosmetic dentures, especially in the aesthetic area.

End User-Based Insights

Based on the end user, the market is bifurcated into hospitals & clinics and ambulatory surgical centers. The hospitals & clinics segment held a larger bio-implants market share in 2023 and the same is anticipated to register a higher CAGR during 2023-2031.

Leading players are implementing strategies such as expansion, partnership, launch of new products, and acquisition of a new customer base for tapping prevailing business opportunities.

In April 2022, Orthopedic Implant Company received approval from the Food and Drug Administration and released the high valve dorsal scanning plate. The product helped expand the company's orthopedic trauma portfolio for the potential clinical implantation of OIC's DRPx Wrist Fracture Plating System, reinforcing it as one of the most comprehensive and value-driven alternatives to any other premium-priced plating systems.

In January 2022, Johnson & Johnson Medical Devices Companies (JJMDC) collaborated with Microsoft to enhance and further develop JJMDC's secure and compliant digital surgery ecosystem.

In October 2021, ScottCare Cardiovascular Solutions signed an agreement with Ninety One Holding, Inc. to become the primary distributor for Ninety One's cloud software platform for monitoring cardiac implanted devices, providing an effective expansion partnership between the two companies. This allows ScottCare Cardiocular Solutions to offer Ninety One's cloud platform directly to clinics that work with their staff to monitor and manage patient data. Ninety One's software platform helps in combining advanced data science with the latest technologies to help analyze and manage complex medical data for patients with implanted cardiac devices.

The US Food and Drug Administration, Centers for Disease Control and Prevention (CDC), and Global Burden of Disease Study, are among the primary and secondary sources referred to while preparing the bio-implants market report.

1. Introduction

1.1 Scope of the Study
1.2 Market Definition, Assumptions and Limitations
1.3 Market Segmentation

2. Executive Summary

2.1 Key Insights
2.2 Market Attractiveness Analysis

3. Research Methodology

4. Bio Implants Market Landscape

4.1 Overview
4.2 PEST Analysis
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain

5. Bio Implants Market - Key Market Dynamics

5.1 Key Market Drivers
5.2 Key Market Restraints
5.3 Key Market Opportunities
5.4 Future Trends
5.5 Impact Analysis of Drivers and Restraints

6. Bio Implants Market - Global Market Analysis

6.1 Bio Implants - Global Market Overview
6.2 Bio Implants - Global Market and Forecast to 2031

7. Bio Implants Market - Revenue Analysis (USD Million) - By Type, 2021-2031

7.1 Overview
7.2 Cardiovascular Implants
7.3 Spinal Implants
7.4 Orthopedics Implants
7.5 Dental Implants
7.6 Ophthalmic Implants
7.7 Others

8. Bio Implants Market - Revenue Analysis (USD Million) - By Material, 2021-2031

8.1 Overview
8.2 Metal
8.3 Ceramics
8.4 Polymers

9. Bio Implants Market - Revenue Analysis (USD Million) - By End User, 2021-2031

9.1 Overview
9.2 Hospitals and Clinics
9.3 Ambulatory Surgical Centers

10. Bio Implants Market - Revenue Analysis (USD Million), 2021-2031 - Geographical Analysis

10.1 North America
- 10.1.1 North America Bio Implants Market Overview
- 10.1.2 North America Bio Implants Market Revenue and Forecasts to 2031
- 10.1.3 North America Bio Implants Market Revenue and Forecasts and Analysis - By Type
- 10.1.4 North America Bio Implants Market Revenue and Forecasts and Analysis - By Material
- 10.1.5 North America Bio Implants Market Revenue and Forecasts and Analysis - By End User
- 10.1.6 North America Bio Implants Market Revenue and Forecasts and Analysis - By Countries
  - 10.1.6.1 United States Bio Implants Market
    - 10.1.6.1.1 United States Bio Implants Market, by Type
    - 10.1.6.1.2 United States Bio Implants Market, by Material
    - 10.1.6.1.3 United States Bio Implants Market, by End User
  - 10.1.6.2 Canada Bio Implants Market
    - 10.1.6.2.1 Canada Bio Implants Market, by Type
    - 10.1.6.2.2 Canada Bio Implants Market, by Material
    - 10.1.6.2.3 Canada Bio Implants Market, by End User
  - 10.1.6.3 Mexico Bio Implants Market
    - 10.1.6.3.1 Mexico Bio Implants Market, by Type
    - 10.1.6.3.2 Mexico Bio Implants Market, by Material
    - 10.1.6.3.3 Mexico Bio Implants Market, by End User

Note - Similar analysis would be provided for below mentioned regions/countries

10.2 Europe
- 10.2.1 Germany
- 10.2.2 France
- 10.2.3 Italy
- 10.2.4 Spain
- 10.2.5 United Kingdom
- 10.2.6 Rest of Europe
10.3 Asia-Pacific
- 10.3.1 Australia
- 10.3.2 China
- 10.3.3 India
- 10.3.4 Japan
- 10.3.5 South Korea
- 10.3.6 Rest of Asia-Pacific
10.4 Middle East and Africa
- 10.4.1 South Africa
- 10.4.2 Saudi Arabia
- 10.4.3 U.A.E
- 10.4.4 Rest of Middle East and Africa
10.5 South and Central America
- 10.5.1 Brazil
- 10.5.2 Argentina
- 10.5.3 Rest of South and Central America

11. Industry Landscape

11.1 Mergers and Acquisitions
11.2 Agreements, Collaborations, Joint Ventures
11.3 New Product Launches
11.4 Expansions and Other Strategic Developments

12. Competitive Landscape

12.1 Heat Map Analysis by Key Players
12.2 Company Positioning and Concentration

13. Bio Implants Market - Key Company Profiles

13.1 LifeNet Health
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments

Note - Similar information would be provided for below list of companies